case_images: PMC4185885_01
case_images: Figure 1. (A) Clinical course from the beginning of the GPC3 peptide vaccination. Serum levels of CA125 and CA72-4 decreased after the initiation of therapy. Black arrows indicate vaccinations. The asterisk indicates right inguinal lymph node resection biopsy. The double asterisk indicates bilateral inguinal lymphadenectomy. (B) Contrast-enhanced CT scan showing liver (white, red, blue, and orange arrows) and paraaortic lymph node (yellow arrows) metastases. The size of metastases increased immediately following the initiation of the GPC3 peptide vaccination; however, tumor sizes decreased markedly within three months. (C, D) Pathological findings of primary ovarian carcinoma (C) and right inguinal lymph node biopsy specimens (D). A microscopy image of a hematoxylin and eosin (H&E)-stained section shows CCC (a, i). Immunohistochemical staining for GPC3 and HLA class I showed positivity in the primary ovarian carcinoma, respectively (b, c). Most CCC cells in the resected right inguinal lymph node metastasis appeared to lack GPC3 expression and a reduction in the expression of HLA class I (ii, iii). Immunohistochemical analysis showed a few CD8-positive T cells in the primary ovarian CCC tissue (d), whereas there was little infiltration of CD8-positive T cells in the resected right inguinal lymph node metastasis (iv). Original magnification, x200.
case_images: hvi-10-338-g1.jpg
case_images: PMC4185885_01_hvi-10-338-g1.jpg
case_images: F1
case_images: The serum levels of these tumor markers decreased after the initiation of treatment (Fig. 1A). Liver and para-aortic lymph node metastases were no longer visible on contrast-enhanced CT after 23 wk of exposure to the vaccine (Fig. 1B). I, and CD8. Immunohistochemical staining revealed the expression of GPC3 and HLA class I in the cytoplasm and membranes of carcinoma cells and a few CD8-positive T cells in the primary ovarian CCC tissue (Fig. 1C), whereas most CCC cells in the resected right inguinal lymph node metastasis appeared to lack GPC3 expression, showed a reduction in the expression of HLA class I, and there was little infiltration of CD8-positive T cells (Fig. 1D).
case_images: PMC4185885_02
case_images: Figure 2. (A) Clinical course from the beginning of the GPC3 peptide vaccination. Serum levels of CA19-9 and CA125 decreased after the 7th vaccination. The CA19-9 level decreased to within the normal range. Black arrows indicate vaccinations. (B) Plain CT and 18F-FDG PET/CT scans showing retroperitoneal lymph node (white, red, blue and orange arrows) and Virchow's node (yellow arrows) metastases. These metastases were negative on 18F-FDG PET/CT at week 49. (C) Pathological findings of primary ovarian carcinoma. A microscopy image of a hematoxylin and eosin (H&E)-stained section shows CCC (a). Immunohistochemical staining was performed for GPC3, HLA class I, and CD8. (b, c, d). The expression of HLA class I was positive, while that of GPC3 was not, and there was no infiltration of CD8-positive T cells. Original magnification, x200.
case_images: hvi-10-338-g2.jpg
case_images: PMC4185885_02_hvi-10-338-g2.jpg
case_images: F2
case_images: CA19-9 levels had decreased to within the normal range by week 43 (Fig. 2A). However, she showed PR at week 37 (Fig. 2B). The expression of HLA class I was positive, while that of GPC3 was not positive in the primary ovarian CCC tissue, and there was no infiltration of CD8-positive T cells (Fig. 2C).